DEXAMETHASONE SODIUM PHOSPHATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H28FO8P.2Na
Molecular Weight	516.4055
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of DEXAMETHASONE SODIUM PHOSPHATE

Structure Search

SMILES

C[C@]1([H])C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@]3([C@]([H])(C[C@]2(C)[C@]1(C(=O)COP(=O)([O-])[O-])O)O)F.[Na+].[Na+]

InChI

InChIKey=PLCQGRYPOISRTQ-FCJDYXGNSA-L

InChI=1S/C22H30FO8P.2Na/c1-12-8-16-15-5-4-13-9-14(24)6-7-19(13,2)21(15,23)17(25)10-20(16,3)22(12,27)18(26)11-31-32(28,29)30;;/h6-7,9,12,15-17,25,27H,4-5,8,10-11H2,1-3H3,(H2,28,29,30);;/q;2*+1/p-2/t12-,15+,16+,17+,19+,20+,21+,22+;;/m1../s1

HIDE SMILES / InChI

Molecular Formula	C22H28FO8P
Molecular Weight	470.4259
Charge	-2
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	8 / 8
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/13422slr035_maxidex_lbl.pdfhttp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004071/WC500204050.pdf
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/67018038

Dexamethasone acetate (NEOFORDEX®) is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune response. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and with proteasome inhibitor (e.g. bortezomib).

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Glucocorticoid receptor 167 Target ID: CHEMBL2034 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10551779 \| https://www.ncbi.nlm.nih.gov/pubmed/16971495 \| https://www.ncbi.nlm.nih.gov/pubmed/2226278	Agonist 2470	4.6 nM [Kd]
Glucocorticoid receptor 167 Target ID: CHEMBL2034 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004071/WC500204050.pdf	Agonist 2470	3.7 nM [Kd]
Mineralocorticoid receptor 49 Target ID: CHEMBL1994 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004071/WC500204050.pdf	Agonist 2470	0.73 nM [Kd]

Conditions

Condition	Modality	Highest Phase	Product
Allergic conjunctivitis 92 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/13422slr035_maxidex_lbl.pdf	Primary	Approved 8043	MAXIDEX Approved Use For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae. Launch Date -2.377728E11
Acne rosacea 42 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/13422slr035_maxidex_lbl.pdf	Primary	Approved 8043	MAXIDEX Approved Use Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. Launch Date -2.37859193E11
Superficial punctate keratitis 40 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/13422slr035_maxidex_lbl.pdf	Primary	Approved 8043	MAXIDEX Approved Use For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae. Launch Date -2.377728E11
Herpes zoster keratitis 42 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/13422slr035_maxidex_lbl.pdf	Primary	Approved 8043	MAXIDEX Approved Use For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae. Launch Date -2.377728E11
Iritis 40 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/13422slr035_maxidex_lbl.pdf	Primary	Approved 8043	MAXIDEX Approved Use For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae. Launch Date -2.37859193E11
Cyclitis 20 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/13422slr035_maxidex_lbl.pdf	Primary	Approved 8043	MAXIDEX Approved Use For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae. Launch Date -2.377728E11
Corneal injury 20 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/13422slr035_maxidex_lbl.pdf	Primary	Approved 8043	MAXIDEX Approved Use For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae. Launch Date -2.377728E11
Bacterial conjunctivitis 32 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/13422slr035_maxidex_lbl.pdf	Primary	Approved 8043	MAXIDEX Approved Use For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae. Launch Date -2.377728E11
Multiple myeloma 145 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004071/WC500204050.pdf	Primary	Approved 8043	Neofordex Approved Use Neofordex is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Launch Date 1.45799997E12

C_max

Value	Dose	Co-administered	Analyte	Population
9.87 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22047811	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:		DEXAMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
51.2 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22047811	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:		DEXAMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
3.93 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22047811	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:		DEXAMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
30% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3806166			DEXAMETHASONE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
96 mg multiple, oral (total) Dose: 96 mg Route: oral Route: multiple Dose: 96 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31139529	unhealthy, 63 years (range: 30–78 years) n = 21 Health Status: unhealthy Age Group: 63 years (range: 30–78 years) Sex: M+F Population Size: 21 Sources: https://pubmed.ncbi.nlm.nih.gov/31139529	Sources: https://pubmed.ncbi.nlm.nih.gov/31139529
0.1 % 3 times / day multiple, ophthalmic Dose: 0.1 %, 3 times / day Route: ophthalmic Route: multiple Dose: 0.1 %, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25135542	unhealthy, 68.3 years (range: 51.0 - 83.0 years) n = 77 Health Status: unhealthy Age Group: 68.3 years (range: 51.0 - 83.0 years) Sex: M+F Population Size: 77 Sources: https://pubmed.ncbi.nlm.nih.gov/25135542	Other AEs: Corneal erosion... Other AEs: Corneal erosion (10%) Sources: https://pubmed.ncbi.nlm.nih.gov/25135542
0.6 mg/kg single, oral Dose: 0.6 mg/kg Route: oral Route: single Dose: 0.6 mg/kg Sources: https://clinicaltrials.gov/ct2/show/NCT02794441	unhealthy, children n = 6 Health Status: unhealthy Condition: Migraine Age Group: children Population Size: 6 Sources: https://clinicaltrials.gov/ct2/show/NCT02794441	Other AEs: Constipation... Other AEs: Constipation (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT02794441
10 mg single, intravenous Dose: 10 mg Route: intravenous Route: single Dose: 10 mg Sources: https://clinicaltrials.gov/ct2/show/NCT00122278	unhealthy n = 106 Health Status: unhealthy Condition: Migraine Population Size: 106 Sources: https://clinicaltrials.gov/ct2/show/NCT00122278	Other AEs: Drowsiness, Dizziness... Other AEs: Drowsiness (below serious, 19 patients) Dizziness (below serious, 3 patients) Adverse drug reaction NOS (below serious, 10 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00122278
12 mg 1 times / day multiple, intravenous Dose: 12 mg, 1 times / day Route: intravenous Route: multiple Dose: 12 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02271698	unhealthy n = 10 Health Status: unhealthy Condition: Knee Arthroplasty Population Size: 10 Sources: https://clinicaltrials.gov/ct2/show/NCT02271698	Other AEs: Wound dehiscence... Other AEs: Wound dehiscence (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT02271698
20 mg single, intravenous Dose: 20 mg Route: intravenous Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/33743063	unhealthy Health Status: unhealthy Sources: https://pubmed.ncbi.nlm.nih.gov/33743063	Sources: https://pubmed.ncbi.nlm.nih.gov/33743063
24 mg 1 times / day multiple, intravenous Dose: 24 mg, 1 times / day Route: intravenous Route: multiple Dose: 24 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02271698	unhealthy n = 10 Health Status: unhealthy Condition: Knee Arthroplasty Population Size: 10 Sources: https://clinicaltrials.gov/ct2/show/NCT02271698	Other AEs: Dizziness... Other AEs: Dizziness (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT02271698
8 mg 1 times / day multiple, oral Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01248585	unhealthy n = 147 Health Status: unhealthy Condition: Radiation-Induced Pain Flare Population Size: 147 Sources: https://clinicaltrials.gov/ct2/show/NCT01248585	Other AEs: Constipation, Dyspepsia... Other AEs: Constipation (below serious, 47 patients) Dyspepsia (below serious, 12 patients) Vomiting (below serious, 9 patients) Fatigue (below serious, 58 patients) Cholesterol high (below serious, 8 patients) Anorexia (below serious, 15 patients) Anxiety (below serious, 11 patient) Insomnia (below serious, 26 patients) Cough (below serious, 9 patients) Dyspnea (below serious, 20 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT01248585
8 mg single, intravenous Dose: 8 mg Route: intravenous Route: single Dose: 8 mg Sources: https://clinicaltrials.gov/ct2/show/NCT01734161	pregnant n = 55 Health Status: pregnant Sex: F Population Size: 55 Sources: https://clinicaltrials.gov/ct2/show/NCT01734161	Other AEs: Incision site bleeding, Body temperature decrease... Other AEs: Incision site bleeding (below serious, 1 patient) Body temperature decrease (below serious, 2 patients) Shivering (below serious, 1 patient) Tachycardia (below serious, 1 patient) Transfusion (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT01734161

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 707 substrate 1601

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OAT1 554		UGT1A1 65 UGT1A5 20 UGT1A6 33 UGT2B1 20 BCRP 71 P-gp 248 OAT1 25 MRP4 30 MRP1 47 MRP2 107 MRP3 53 MRP5 21 ABCC12 21

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
ABCC12 21	inducer 1440 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
MRP1 166	inducer 1440 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
MRP2 434	inducer 1440 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
MRP3 200	inducer 1440 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
MRP5 45	inducer 1440 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
OAT1 558	inducer 1440 Sources: https://www.sciencedirect.com/science/article/pii/S1931524413002557 Page: -	no
OAT1 558	inhibitor 3045 Sources: https://www.sciencedirect.com/science/article/pii/S1931524413002557 Page: -	no
UGT1A6 136	inducer 1440 Sources: https://link.springer.com/article/10.1023%2FA%3A1018812021549 Page: -	no
BCRP 713	inducer 1440 Sources: https://journals.physiology.org/doi/full/10.1152/ajpcell.00491.2007 Page: -	yes
MRP4 226	inducer 1440 Sources: https://www.sciencedirect.com/science/article/pii/S1931524413002557 Page: -	yes
P-gp 1514	inducer 1440 Sources: https://journals.physiology.org/doi/full/10.1152/ajpcell.00491.2007 Page: -	yes
UGT1A1 240	inducer 1440 Sources: https://link.springer.com/article/10.1023/B:MOLE.0000043582.35335.ff Page: -	yes
UGT1A5 20	inducer 1440 Sources: https://link.springer.com/article/10.1023%2FA%3A1018812021549 Page: -	yes
UGT2B1 21	inducer 1440 Sources: https://link.springer.com/article/10.1023%2FA%3A1018812021549 Page: -	yes
CYP3A4 1772	inducer 1440 Sources: https://ascpt.onlinelibrary.wiley.com/doi/full/10.1067/mcp.2000.110215 Page: -	yes	yes (co-administration study) Comment: These data demonstrate that dexamethasone at doses used clinically increased CYP3A4 activity with extensive intersubject variability and that the extent of CYP3A4 induction was, in part, predicted by the baseline activity of CYP3A4 in both healthy volunteers and human hepatocyte cultures. Sources: https://ascpt.onlinelibrary.wiley.com/doi/full/10.1067/mcp.2000.110215 Page: -

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1601	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/17124593/ Page: -	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:41879	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:41879
ChemicalBook	CB4261243	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4261243
MolPort	MolPort-003-846-433	https://www.molport.com/shop/molecule-link/MolPort-003-846-433
Selleck Chemicals	Dexamethasone	http://www.selleckchem.com/products/Dexamethasone.html
ZINC	ZINC000003875332	http://zinc15.docking.org/substances/ZINC000003875332
eMolecules	29541178	https://www.emolecules.com/cgi-bin/more?vid=29541178
eMolecules	30067429	https://www.emolecules.com/cgi-bin/more?vid=30067429
eMolecules	31411022	https://www.emolecules.com/cgi-bin/more?vid=31411022
eMolecules	497104	https://www.emolecules.com/cgi-bin/more?vid=497104

PubMed

Title	Date	PubMed
Effects of dexamethasone on tumor-induced brain edema and its distribution in the brain of monkeys.	1979 Mar	106094
ECC-1 human endometrial cells as a model system to study dioxin disruption of steroid hormone function.	1999 Apr	10478797
Glucocorticoids inhibit proliferation and adhesion of the IL-3-dependent mast cell line, MC/9, to NIH/3T3 fibroblasts, with an accompanying decrease in IL-3 receptor expression.	1999 Apr	10335920
Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA.	1999 Aug 12	10467400
The glucocorticoid receptor is essential for maintaining basal and dexamethasone-induced repression of the murine corticosteroid-binding globulin gene.	1999 Aug 20	10509797
Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation.	1999 Feb	10084258
Dexamethasone induced alterations in the levels of proteases involved in blood pressure homeostasis and blood coagulation in rats.	1999 Jul	10485340
[Iatrogenic Cushing syndrome and mutatio tarda caused by dexamethasone containing nose drops].	1999 Jul	10463118
Induction of stromelysin gene expression by tumor necrosis factor alpha is inhibited by dexamethasone, salicylate, and N-acetylcysteine in synovial fibroblasts.	1999 Jun	10336562
Nitric oxide, superoxide radicals and mast cells in pathogenesis of indomethacin-induced small intestinal lesions in rats.	1999 Mar	10210152
Pharmacological validation of a feline model of steroid-induced ocular hypertension.	1999 Mar	10088814
Intestinal damage induced by zinc deficiency is associated with enhanced CuZn superoxide dismutase activity in rats: effect of dexamethasone or thyroxine treatment.	1999 May	10381190
Effect of arsenite on induction of CYP1A, CYP2B, and CYP3A in primary cultures of rat hepatocytes.	1999 May 15	10329507
Effects of theophylline, dexamethasone and salbutamol on cytokine gene expression in human peripheral blood CD4+ T-cells.	1999 Nov	10596698
Early (4-7 days of age) dexamethasone therapy for prevention of chronic lung disease in preterm infants.	1999 Nov	10516395
Pharmacological and histopathological study of cyclophosphamide-induced hemorrhagic cystitis - comparison of the effects of dexamethasone and Mesna.	1999 Oct	10510257
Dexamethasone increases eNOS gene expression and prevents renal vasoconstriction induced by cyclosporin.	1999 Sep	10484530
Melatonin regulates glucocorticoid receptor: an answer to its antiapoptotic action in thymus.	1999 Sep	10463946
Morphine induced allodynia in a child with brain tumour.	1999 Sep 4	10473483
Dexamethasone enhances ras-recision gene expression in cultured murine fetal lungs: role in development.	2000 Aug	10926554
Dexamethasone suppresses tumor necrosis factor-alpha-induced apoptosis in osteoblasts: possible role for ceramide.	2000 Aug	10919278
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.	2000 Aug 1	10910927
Dexamethasone-suppressible hypertension.	2000 Aug 26	11085685
Low doses of oral dexamethasone for hormone-refractory prostate carcinoma.	2000 Dec 15	11135218
Antenatal dexamethasone enhances endothelin receptorB expression in hypoplastic lung in nitrofen-induced diaphragmatic hernia in rats.	2000 Feb	10693666
Inhibition of carrageenan-induced edema by indomethacin or sodium salicylate does not prevent the increase of nerve growth factor in the rat hind paw.	2000 Jan 14	10653021
Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review.	2000 Jul 29	10915127
Dexamethasone induced cardiac hypertrophy in newborn rats is accompanied by changes in myosin heavy chain phenotype and gene transcription.	2000 Jun	10942214
Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up.	2000 Jun	10923861
Combined administration of G-CSF and dexamethasone for the mobilization of granulocytes in normal donors: optimization of dosing.	2000 Jun	10864982
Down-regulation of thyroid transcription factor-1 gene expression in fetal lung hypoplasia is restored by glucocorticoids.	2000 Jun	10830305
Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line.	2000 Mar	10696073
Ticlopidine-induced aplastic anemia: development of chromosomal abnormalities and response to immunosuppressive therapy.	2000 Mar	10679804
Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone.	2000 May-Jun	10864051
Corticosteroids and cognitive function in humans: methodological considerations.	2000 May-Jun	10864049
Regulation of leptin release by troglitazone in human adipose tissue.	2000 Nov	11092516
Efficacy of galectins in the amelioration of nephrotoxic serum nephritis in Wistar Kyoto rats.	2000 Nov	11044214
Endocrinologic and psychological effects of short-term dexamethasone in anorexia nervosa.	2000 Sep	11082797
Modification of biophysical properties of lung epithelial Na(+) channels by dexamethasone.	2000 Sep	10942727
Involvement of tyrosine hydroxylase up regulation in dexamethasone-induced hypertension of rats.	2000 Sep 8	11072875
Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma.	2009 Jul 1	19549772
Triptolide enhances the sensitivity of multiple myeloma cells to dexamethasone via microRNAs.	2012 Jun	22260163
Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone.	2012 Jun	22207485
CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.	2012 Nov	22906694

Patents

Sample Use Guides

In Vivo Use Guide

One or two drops topically in the conjunctival sac(s). In severe disease, drops may be used hourly. In mild disease, drops may be used up to four to six times daily.

Route of Administration: Other

In Vitro Use Guide

Caco-2 cells were treated with 1 μM dexamethasone and SGK1 mRNA levels were determined by Northern blot analysis. Figure 1A shows that dexamethasone rapidly induced SGK1 mRNA expression as early as 30 min and maintained the elevated expression for at least 24 h.

Substance Class	Chemical Created by `admin` on `Fri Jun 25 21:03:56 UTC 2021` Edited by `admin` on `Fri Jun 25 21:03:56 UTC 2021`
Record UNII	AI9376Y64P
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DEXAMETHASONE SODIUM PHOSPHATE

Common Name

English

DEXAMETHASONE SODIUM PHOSPHATE [VANDF]

Common Name

English

DEXABENE

Brand Name

English

MEPHAMESONE

Brand Name

English

DEXADRESON

Common Name

English

DEXAMETHASONE SODIUM PHOSPHATE [WHO-DD]

Common Name

English

DEXAMETHASONE SODIUM PHOSPHATE [WHO-IP]

Common Name

English

MEGACORT

Common Name

English

ORADEXON

Brand Name

English

TLC-399

Code

English

DEXACORT

Brand Name

English

DEXAMETHASONE DISODIUM PHOSPHATE

Common Name

English

PRODEX

Brand Name

English

9-FLUORO-11.BETA.,17,21-TRIHYDROXY-16.ALPHA.-METHYLPREGNA-1,4-DIENE-3,20-DIONE 21-(DIHYDROGEN PHOSPHATE) DISODIUM SALT

Common Name

English

SOLUDECADRON

Brand Name

English

PREGNA-1,4-DIENE-3,20-DIONE, 9-FLUORO-11,17-DIHYDROXY-16-METHYL-21-(PHOSPHONOOXY)-, DISODIUM SALT, (11.BETA.,16.ALPHA.)-

Common Name

English

TLC399

Code

English

AK-DEX

Brand Name

English

DALALONE

Brand Name

English

DEXAMETHASONE SODIUM PHOSPHATE [JAN]

Common Name

English

NSC-756722

Code

English

DEXAMETHASONE SODIUM PHOSPHATE [GREEN BOOK]

Common Name

English

DEXAMETHASONE PHOSPHATE (AS SODIUM)

Common Name

English

TOTOCORTIN

Brand Name

English

DEXACEN-4

Brand Name

English

DEXAMETHASONE 21-PHOSPHATE DISODIUM SALT [MI]

Common Name

English

ORGADRONE

Brand Name

English

SOLDESAM

Brand Name

English

NEODECADRON COMPONENT DEXAMETHASONE SODIUM PHOSPHATE

Common Name

English

DEXAIR

Brand Name

English

DEXAMETHASONE SODIUM PHOSPHATE [USP MONOGRAPH]

Common Name

English

DEXAMETHASONE SODIUM PHOSPHATE COMPONENT OF NEODECADRON

Common Name

English

DEXAMETHASONE SODIUM PHOSPHATE [ORANGE BOOK]

Common Name

English

DEXAMETHASONE 21-PHOSPHATE DISODIUM SALT

Common Name

English

TURBINAIRE

Common Name

English

SOLUPEN N

Brand Name

English

DEXAMETHASONI NATRII PHOSPHAS [WHO-IP LATIN]

Common Name

English

DEXAMETHASONE SODIUM PHOSPHATE [USP-RS]

Common Name

English

DECADRON PHOSPHATE

Brand Name

English

DEXAMETHASONE SODIUM PHOSPHATE [MART.]

Common Name

English

DEXAMETHASONE SODIUM PHOSPHATE [USP]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

373212